Natco Pharma gets USFDA approval for Visakhapatnam facility

0
90
natco-pharma-gets-usfda-approval-for-visakhapatnam-facility

By Economic Times – Natco Pharma gets USFDA approval for Visakhapatnam facility PharmaceuticalsStock Analysis, IPO, Mutual Funds, Bonds & MoreHyderabad-based Natco Pharma Ltd on Tuesday said it has received the final approval from the US health regulator for its first supplemental abbreviated new drug application (sANDA) filed from its new drug formulations facility at Visakhapatnam, Andhra Pradesh.PTI|Last Updated: Apr 28, 2020, 12.55 PM ISTAgenciesThe company, hwoever, did not disclose the product which has been approved by the US Food and Drug Administration (USFDA) to be produced from the facility.NEW DELHI: Hyderabad-based Natco Pharma Ltd on Tuesday said it has received the final approval from the US health regulator for its first supplemental abbreviated new drug application (sANDA) filed from its new drug formulations facility at Visakhapatnam, Andhra Pradesh.

The sANDA, submitted as ‘prior approval supplement’ provides for Natco’s formulations facility at JNPC SEZ, Ramky Pharma City in Visakhapatnam as an alternate site for manufacture of the approved drug product for the US market, Natco Pharma said in a regulatory filing.

The company, hwoever, did not disclose the product which has been approved by the US Food and Drug Administration (USFDA) to be produced from the facility.
Also ReadRINL shuts down two blast furnaces at Visakhapatnam plantVisakhapatnam: City’s history on offer at restored lighthouseVisakhapatnam homes now turn ‘smart’ with Internet-linked devicesRINL-Visakhapatnam Steel Plant continues its operations, takes measures to combat Covid-19Commenting feature is disabled in your country/region. Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service

For more details, please visit http://gestyy.com/w99Wrf

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.